This Article Full Text Full Text (PDF) All Versions of this Article: 1535-7163.MCT-06-0392v1 6/1/213    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Punchihewa, C. Articles by Yang, D. Search for Related Content PubMed PubMed Citation Articles by Punchihewa, C. Articles by Yang, D.

Research Articles: Therapeutics, Targets, and Development

XR5944: A potent inhibitor of estrogen receptors

¹ College of Pharmacy, The University of Arizona; ² Arizona Cancer Center, Tucson, Arizona; ³ Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia; and ⁴ BIO5 Institute, The University of Arizona, Tucson, Arizona

Requests for reprints: Danzhou Yang, College of Pharmacy, University of Arizona, 1703 East Mabel Street, Tucson, AZ 85721. Phone: 520-626-5969; Fax: 520-626-6988. E-mail: yangd{at}pharmacy.arizona.edu

Abstract

The anticancer drug XR5944 was originally developed as a topoisomerase inhibitor and was subsequently shown to be a transcription inhibitor. It has shown exceptional anticancer activity both in vitro and in vivo and was significantly more potent than traditional topoisomerase inhibitors. The solution structure of the XR5944/DNA complex recently obtained in our laboratory indicates that XR5944 bis-intercalates at the 5'-(TpG):(CpA) site of duplex DNA, which is found in the consensus DNA-binding site of estrogen receptor (ER). Thus, we tested the ability of XR5944 to inhibit ER activity both in vitro and in cultured cells. In electrophoretic mobility shift assays, it is seen that the DNA binding of recombinant ER protein, as well as ER from nuclear extracts, is inhibited by XR5944 in a dose-dependent manner. In luciferase reporter assays, XR5944 inhibited the reporter gene expression from an estrogen response element–containing promoter but not from a basal promoter sequence that lacks any cis-acting elements. In contrast, the RNA polymerase inhibitor actinomycin D inhibits the transcription from both the above-mentioned promoters. The specificity of XR5944 activity is displayed by a separate reporter assay in which the transactivation of reporter gene expression by Sp1 proteins was not inhibited by XR5944. Collectively, these data suggest that XR5944 is capable of specifically inhibiting the binding of ER to its consensus DNA sequence and its subsequent activity. This represents a novel mechanism of ER inhibition, which may allow the development of agents capable of overcoming resistance to current antiestrogens. [Mol Cancer Ther 2007;6(1):213–9]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/ 7/06; revised 11/14/06; accepted 11/14/06.